CIBC Innovation Banking announced it has provided growth capital financing to EnsoData, a healthcare technology company focused on advancing sleep medicine through artificial intelligence solutions. The financing is expected to support EnsoData’s continued expansion and accelerate investment in AI-driven diagnostics technology.
Based in Madison, Wisconsin, EnsoData develops FDA-cleared AI-powered software designed to simplify sleep diagnosis and improve access to care. Its flagship product, EnsoHST, is a multi-night home sleep testing solution that combines a wearable device with a mobile application to deliver clinically reliable diagnostic results. The platform automates analysis and streamlines workflows to help clinicians expand patient capacity, accelerate diagnoses, and improve outcomes.
EnsoData said its technology supports the full sleep care continuum, including diagnosis and long-term patient management. The company is also exploring broader applications for its AI technology across additional clinical areas. According to the company, its platform has supported the care of more than 2.9 million patients to date.
CIBC Innovation Banking said it has more than 25 years of experience supporting growth-stage technology and life sciences companies across North America and currently manages over $11 billion in funds across sectors including healthcare, life sciences, and cleantech.
KEY QUOTES:
“This facility from CIBC Innovation Banking enables EnsoData to expand access to the sleep care pathway today, while accelerating our investment in AI-driven innovations that will shape the future of diagnostics across multiple clinical domains.”
Matt Dobereiner, CFO, EnsoData
“CIBC Innovation Banking is very glad to support EnsoData’s growth and continued adoption among sleep medicine professionals. EnsoData is at the exciting intersection of leveraging AI and machine-learning technology to improve access for patients to the care pathway.”
Andrew Schwartz, Managing Director, CIBC Innovation Banking
